Ixico wins contract from new European biopharmaceutical client

Medical imaging analytics company Ixico has been selected to provide PET and MRI imaging services to an unnamed “leading European biopharmaceutical company” specialising in neurodegenerative conditions, it announced on Tuesday.

The AIM-traded firm said the trial was a phase 1b and 2 clinical trial, and related to the use of a novel compound to target amyloid in neurodegenerative diseases.

It said the sponsor was a new client for Ixico, with the trial set to run over about five years.

The study would include participants with Alzheimer's disease, as well as participants with Down’s syndrome.

Ixico would provide end-to-end support to the sponsor for the trial, from consultation in planning and design of the imaging protocols to the set-up and management of imaging centres, collection and control of imaging data, radiology and subsequent analysis and reporting of data.

“Our success in being awarded this study with another new client follows on from our success in securing contracts with nine new clients during the last financial year and is a further contract that utilises both our MRI and PET service portfolios,” said chief executive officer Giulio Cerroni.

“Our mission is to support our clients in their tireless efforts to bring potential treatments to patients suffering from neurological disorders, and this contract reflects the confidence that increasing numbers of companies are placing in Ixico as their trusted neuroimaging partner for their important CNS studies.”

At 1412 GMT, shares in Ixico were up 2.07% at 46.44p.